Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume 1 2011”. The report is an essential source of information and analysis on the global bladder cancer therapeutics market. The report provides comprehensive information on bladder cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global bladder cancer therapeutics market. It analyses the treatment usage patterns in the global bladder cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global bladder cancer sector. It quantifies the unmet need in the global bladder cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The global bladder cancer therapeutics market is moderately attractive and is primarily driven by growth in the patient volume and growth in the cost of therapy. The patient volume was driven by growth in treatment usage pattern measurements such as diseased population, treatment seeking population, diagnosis population and prescription population. In 2010, the bladder cancer therapeutics market in the key markets was worth $610m. The market’s size is driven by two key parameters, namely the patient volume and the annual cost of therapy per patient. Between 2001 and 2010, the global bladder cancer therapeutics market grew at a CAGR of 8.0%. The bladder cancer therapeutics market is completely dominated by generic drugs such as methotrexate, cisplatin, vinblastin and doxorubicin. BCG therapy and mitomycin C are the other drugs that are used for the treatment of bladder cancer. Gemcitabine was the top-selling drug in the bladder cancer therapeutics market in 2010. The other leading drugs in the market in 2001 were BCG therapy and methotrexate.

Scope

• An overview of bladder cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized global bladder cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
• Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
• Competitor assessment including drug launch analysis and drug sales forecasts.
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
• Analysis of unmet need in the market and target product profile including opportunity for target product.
• Technology trends analytic framework to assess strength of pipeline.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include dual kinase inhibitors, EGFR inhibitors, microtubule inhibitors, DNA synthesis inhibitors.
• Clinical trials mapping of trials for bladder cancer in different regions.
• An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
• Analysis of the current and future market competition in the global Bladder Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Bristol-Myers Squibb, Spectrum Pharmaceuticals, Inc., Bioniche Life Sciences, Inc., Endo Pharmaceuticals, Eli lilly and Company and Sanofi-aventis.
• Analysis of licensing agreements during 2004-2010 in the bladder cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
• Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
• Direct quotes from key opinion leaders (KOL) or physicians in the bladder cancer therapeutics market.

Reasons to Buy

• Develop business strategies and perform superior market quantification analysis by understanding the trends shaping and driving the global bladder cancer therapeutics market.
• Develop business strategies and perform superior market quantification analysis by understanding treatment preferences of physicians in disease state and across treatment flow.
• Develop business strategies by accessing market sizing, forecasts and quantified growth opportunities in the global bladder cancer therapeutics market till 2020.
• Develop business strategies by quantifying patient population in the global bladder cancer market to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
• Drive revenues by performing benchmarking analysis and growth opportunities against currently marketed products
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by Identifying market entry points based on safety, efficacy, and pricing parameters.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
• Develop and design your in-licensing and out-licensing strategies by taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
• Develop and design your in-licensing and out-licensing strategies by assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
• Develop and design your in-licensing and out-licensing strategies by track drug sales in the global bladder cancer therapeutics market from 2001 to 2020
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• What’s the next big thing in the global bladder cancer therapeutics market landscape? Identify, understand and capitalize

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Bladder Cancer Therapeutics: Introduction
2.1 Bladder Cancer Types
2.2 Bladder Cancer by Cell Type
2.3 Bladder Cancer by Extent of Metastasis
2.4 Symptoms
2.5 Risk factors
2.6 Prognosis
2.7 Diagnosis of Bladder Cancer
2.7.1 Physical Examination
2.7.2 Urological Tests
2.7.3 Cystoscopy and TURBT
2.7.4 Imaging Tests
2.8 Staging of Bladder Cancer
2.9 Treatment of Bladder Cancer
2.10 Treatment of Bladder Cancer
2.10.1 Surgery
2.10.2 TURBT with fulguration
2.10.3 Cystectomy
2.10.4 Radiation Therapy
2.10.5 Immunotherapy
2.10.6 Chemotherapy
2.11 GlobalData Indepth Report Guidance

3 Bladder Cancer Therapeutics: Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Forecasts
3.1.4 Drug Sales
3.2 The US
3.2.1 Market Size
3.2.2 Drivers and Barriers
3.2.3 Forecasts
3.2.4 Drug Sales
3.2.5 Pricing and Reimbursements
3.3 The UK
3.3.1 Market Size
3.3.2 Drivers and Barriers
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.5 Drug Sales
3.3.6 Pricing and Reimbursements
3.4 Germany
3.4.1 Market Size
3.4.2 Drivers and Barriers
3.4.3 Impact on the Market
3.4.4 Forecasts
3.4.5 Drug Sales
3.4.6 Pricing and Reimbursements
3.5 France
3.5.1 Market Size
3.5.2 Drivers and Barriers
3.5.3 Impact on the Market
3.5.4 Forecasts
3.5.5 Drug Sales
3.5.6 Pricing and Reimbursements
3.6 Italy
3.6.1 Market Size
3.6.2 Drivers and Barriers
3.6.3 Impact on the Market
3.6.4 Forecasts
3.6.5 Drug Sales
3.6.6 Pricing and Reimbursements
3.7 Spain
3.7.1 Market Size
3.7.2 Drivers and Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Drug Sales
3.8.6 Pricing and Reimbursements
3.9 Brazil
3.9.1 Market Size
3.9.2 Drivers and Barriers
3.9.3 Impact on the Market
3.9.4 Forecasts
3.9.5 Future Impact
3.9.6 Drug Sales
3.10 India
3.10.1 Market Size
3.10.2 Drivers and Barriers
3.10.3 Impact on the Market
3.10.4 Forecasts
3.10.5 Future Impact
3.10.6 Drug Sales
3.11 China
3.11.1 Market Size
3.11.2 Drivers and Barriers
3.11.3 Impact on the Market
3.11.4 Forecasts
3.11.5 Future Impact
3.11.6 Drug Sales
3.12 Russia
3.12.1 Market Size
3.12.2 Drivers and Barriers
3.12.3 Impact on the Market
3.12.4 Forecasts
3.12.5 Future Impact
3.12.6 Drug Sales
3.13 Key Takeaway

4 Bladder Cancer Therapeutics: Opportunity and Unmet Need
4.1.1 Neoadjuvant Treatment
4.1.2 Metastatic Bladder Cancer Treatment
4.2 Key Takeaway

5 Bladder Cancer Therapeutics – Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile for the Major Marketed Products in the Bladder Cancer Therapeutics Market
5.3.1 TICE BCG
5.3.2 Valstar (Valrubicin)
5.3.3 PLATINOL-AQ (cisplatin Injection)
5.3.4 MVAC (Methotrexate, Vinblastine, Adriamycin & Cisplatin)
5.3.5 Gemcitabine + Cisplatin
5.4 Key Takeaway

6 Bladder Cancer Therapeutics: Pipeline Assessment
6.1 Overview
6.2 Strategic Pipeline Assessment
6.2.1 Technology Trends Analytic Framework
6.3 Bladder Cancer Therapeutics – Promising Drugs Under Clinical Development
6.4 Molecule Profile for Promising Drugs under Clinical Development
6.4.1 Javlor (Bristol-Myers Squibb and Pierre Fabre Medicament SA)
6.4.2 EOquin (Spectrum Pharmaceuticals and Allergan Inc)
6.4.3 Urocidin (Bioniche Life Sciences & Endo Pharma)
6.4.4 Larotaxel (Sanofi-aventis)
6.4.5 OGX-427 (OncoGeneX Inc)
6.5 Bladder Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action
6.6 Bladder Cancer Pipeline – Pipeline by Clinical Phases of Development
6.6.1 Bladder Cancer Therapeutics – Phase III Clinical Pipeline
6.6.2 Bladder Cancer Therapeutics – Phase II Clinical Pipeline
6.6.3 Bladder Cancer Therapeutics – Phase I Clinical Pipeline
6.6.4 Bladder Cancer Therapeutics – Pre-clinical Pipeline
6.6.5 Discontinued / Suspended Drug for Bladder Cancer
6.7 Key Takeaway

7 Bladder Cancer Therapeutics: Clinical Trials Mapping
7.1 Clinical Trials
7.1.1 Clinical Trials by Status
7.1.2 Clinical Trials by Country
7.1.3 Clinical Trials by Phase
7.1.4 Clinical Trials by Sponsor Type
7.1.5 Clinical Trials – Leading Sponsors
7.1.6 Clinical Trials – Leading Company Sponsors by Phase
7.2 Patient Recruitment

8 Bladder Cancer Therapeutics: Implications for Future Market Competition

9 Bladder Cancer Therapeutics: Future Market Players
9.1 Introduction
9.2 Bristol-Myers Squibb Company
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 SWOT Analysis
9.3 Spectrum Pharmaceuticals, Inc.
9.3.1 Business Description
9.3.2 Financial Overview
9.3.3 SWOT Analysis
9.4 Bioniche Life Sciences, Inc.
9.4.1 Business Description
9.4.2 Financial Overview
9.4.3 SWOT Analysis
9.5 Endo Pharmaceuticals Holdings Inc.
9.5.1 Business Description
9.5.2 Financial Overview
9.5.3 SWOT Analysis
9.6 Sanofi-aventis
9.6.1 Business Description
9.6.2 Financial Overview
9.6.3 SWOT Analysis
9.7 Eli Lilly and Company
9.7.1 Business Description
9.7.2 Financial Overview
9.7.3 SWOT Analysis

10 Bladder Cancer Therapeutics: Licensing and Partnership Deals
10.1.1 Partnerships
10.1.2 Licensing Agreements
10.1.3 Terminated Licensing Agreements
10.2 Mergers & Acquisition Analysis
10.2.1 Key Highlights
10.3 Expert Opinion
10.3.1 The US
10.3.2 The UK
10.3.3 Germany
10.3.4 France
10.3.5 Italy

11 Bladder Cancer Therapeutics: Appendix
11.1 Definitions
11.2 Acronyms
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Forecasting
11.3.4 Primary Research
11.3.5 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Bibliography

List of Tables

Table 1: Bladder Cancer – TNM (Tumor Node Metastasis) Staging, 2010
Table 2: Definitions of Stages
Table 3: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2001–2010
Table 4: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2010
Table 5: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2001–2010
Table 6: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2010
Table 7: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020
Table 8: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020
Table 9: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2011–2020
Table 10: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020
Table 11: Bladder Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2010
Table 12: Bladder Cancer Therapeutics Market, Global, Drug Sales ($m), 2011-2020
Table 13: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2001–2010
Table 14: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2010
Table 15: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2001–2010
Table 16: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2001–2010
Table 17: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020
Table 18: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020
Table 19: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2011–2020
Table 20: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020
Table 21: Bladder Cancer Therapeutics Market, The US, Drug Sales ($m), 2001-2010
Table 22: Bladder Cancer Therapeutics Market, The US, Drug Sales ($m), 2011-2020
Table 23: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2001–2010
Table 24: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2001–2010
Table 25: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2001–2010
Table 26: Bladder Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2001–2010
Table 27: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2011-2020
Table 28: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011-2020
Table 29: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2011-2020
Table 30: Bladder Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011-2020
Table 31: Bladder Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2010
Table 32: Bladder Cancer Therapeutics Market, The UK, Drug Sales ($m), 2011-2020
Table 33: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2001–2010
Table 34: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001–2010
Table 35: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2001–2010
Table 36: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2001–2010
Table 37: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2011-2020
Table 38: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020
Table 39: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2011-2020
Table 40: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011-2020
Table 41: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2010
Table 42: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011-2020
Table 43: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2001–2010
Table 44: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2010
Table 45: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2001–2010
Table 46: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2010
Table 47: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2011-2020
Table 48: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020
Table 49: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2011-2020
Table 50: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011-2020
Table 51: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2010
Table 52: Bladder Cancer Therapeutics Market, France, Drug Sales ($m), 2011-2020
Table 53: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2001–2010
Table 54: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001–2010
Table 55: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2001–2010
Table 56: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2001–2010
Table 57: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2011-2020
Table 58: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020
Table 59: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2011-2020
Table 60: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011-2020
Table 61: Bladder Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2010
Table 62: Bladder Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011-2020
Table 63: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2001–2010
Table 64: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001–2010
Table 65: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2001–2010
Table 66: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2001–2010
Table 67: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2011-2020
Table 68: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020
Table 69: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2011-2020
Table 70: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011-2020
Table 71: Bladder Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2010
Table 72: Bladder Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011-2020
Table 73: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2001–2010
Table 74: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2010
Table 75: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2001–2010
Table 76: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2001–2010
Table 77: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2011-2020
Table 78: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020
Table 79: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2011-2020
Table 80: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011-2020
Table 81: Bladder Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2010
Table 82: Bladder Cancer Therapeutics Market, Japan, Drug Sales ($m), 2011-2020
Table 83: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2010
Table 84: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2010
Table 85: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2001–2010
Table 86: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2010
Table 87: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011-2020
Table 88: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020
Table 89: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2011-2020
Table 90: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020
Table 91: Bladder Cancer Therapeutics Market, Brazil, Drug Sales ($m), 2001-2010
Table 92: Bladder Cancer Therapeutics Market, Brazil, Drug Sales ($m), 2011-2020
Table 93: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2001–2010
Table 94: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2010
Table 95: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2001–2010
Table 96: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2010
Table 97: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2011-2020
Table 98: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020
Table 99: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2011-2020
Table 100: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011-2020
Table 101: Bladder Cancer Therapeutics Market, India, Drug Sales ($m), 2001-2010
Table 102: Bladder Cancer Therapeutics Market, India, Drug Sales ($m), 2011-2020
Table 103: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2001–2010
Table 104: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2010
Table 105: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2001–2010
Table 106: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2010
Table 107: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2011-2020
Table 108: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020
Table 109: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2011-2020
Table 110: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011-2020
Table 111: Bladder Cancer Therapeutics Market, China, Drug Sales ($m), 2001-2010
Table 112: Bladder Cancer Therapeutics Market, China, Drug Sales ($m), 2011-2020
Table 113: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2010
Table 114: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2010
Table 115: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2001–2010
Table 116: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2010
Table 117: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2011-2020
Table 118: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020
Table 119: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2011-2020
Table 120: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020
Table 121: Bladder Cancer Therapeutics Market, Russia, Drug Sales ($m), 2001-2010
Table 122: Bladder Cancer Therapeutics Market, Russia, Drug Sales ($m), 2011-2020
Table 123: Major Marketed Products Comparison in the Bladder Cancer Therapeutics Market, 2010
Table 124: Bladder Cancer Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 125: Clinical Trial Results for Javlor, April 2009
Table 126: Bladder Cancer Therapeutics – Phase III Clinical Pipeline
Table 127: Bladder Cancer Therapeutics – Phase II Clinical Pipeline
Table 128: Bladder Cancer Therapeutics – Phase I Clinical Pipeline
Table 129: Bladder Cancer Therapeutics – Pre-clinical Pipeline
Table 130: Bladder Cancer Therapeutics – Discontinued/Suspended Drugs
Table 131: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011
Table 132: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011
Table 133: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011
Table 134: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011
Table 135: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011
Table 136: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011
Table 137: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011
Table 138: Bladder Cancer, Global, Licensing Agreements, 2009-2010

List of Figures

Figure 1: Bladder Cancer Histopathology
Figure 2: Intravenous Pyelogram
Figure 3: Bladder Cancer, CT Scan Image
Figure 4: Bladder Cancer, MRI Image
Figure 5: Treatment Algorithm for Bladder Cancer
Figure 6: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2001–2010
Figure 7: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2010
Figure 8: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2001–2010
Figure 9: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2010
Figure 10: Bladder Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2009
Figure 11: Bladder Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2010
Figure 12: Bladder Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020
Figure 13: Bladder Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020
Figure 14: Bladder Cancer Therapeutics Market, Global, Patient Volume (absolute), 2011–2020
Figure 15: Bladder Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020
Figure 16: Bladder Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2010–2020
Figure 17: Bladder Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2020
Figure 18: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2001–2010
Figure 19: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2010
Figure 20: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2001–2010
Figure 21: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2001–2010
Figure 22: Bladder Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2010
Figure 23: Bladder Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2010
Figure 24: Bladder Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020
Figure 25: Bladder Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020
Figure 26: Bladder Cancer Therapeutics Market, The US, Patient Volume (absolute), 2011–2020
Figure 27: Bladder Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020
Figure 28: Bladder Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2011–2020
Figure 29: Bladder Cancer Therapeutics Market, The US, Drug Sales ($m), 2001-2020
Figure 30: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2001–2010
Figure 31: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2001–2010
Figure 32: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2001–2010
Figure 33: Bladder Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2001–2010
Figure 34: Bladder Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2010
Figure 35: Bladder Cancer Therapeutics Market, the UK, the Impact of Historical Events on the Market, 2010
Figure 36: Bladder Cancer Therapeutics Market, the UK, Sales Value ($m), 2011-2020
Figure 37: Bladder Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011-2020
Figure 38: Bladder Cancer Therapeutics Market, the UK, Patient Volume (absolute), 2011-2020
Figure 39: Bladder Cancer Therapeutics Market, the UK, Treatment Usage Patterns, 2011-2020
Figure 40: Bladder Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011–2020
Figure 41: Bladder Cancer Therapeutics Market, The UK, Drug Sales ($m), 2001-2020
Figure 42: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2001–2010
Figure 43: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001–2010
Figure 44: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2001–2010
Figure 45: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2001–2010
Figure 46: Bladder Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2010
Figure 47: Bladder Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2010
Figure 48: Bladder Cancer Therapeutics Market, Germany, Sales Value ($m), 2011-2020
Figure 49: Bladder Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020
Figure 50: Bladder Cancer Therapeutics Market, Germany, Patient Volume (absolute), 2011-2020
Figure 51: Bladder Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011-2020
Figure 52: Bladder Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011–2020
Figure 53: Bladder Cancer Therapeutics Market, Germany, Drug Sales ($m), 2001-2020
Figure 54: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2001–2010
Figure 55: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2010
Figure 56: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2001–2010
Figure 57: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2010
Figure 58: Bladder Cancer Therapeutics Market, France, Market Drivers and Restraints, 2010
Figure 59: Bladder Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2010
Figure 60: Bladder Cancer Therapeutics Market, France, Sales Value ($m), 2011-2020
Figure 61: Bladder Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020
Figure 62: Bladder Cancer Therapeutics Market, France, Patient Volume (absolute), 2011-2020
Figure 63: Bladder Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011-2020
Figure 64: Bladder Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2011–2020
Figure 65: Bladder Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2020
Figure 66: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2001–2010
Figure 67: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001–2010
Figure 68: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2001–2010
Figure 69: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2001–2010
Figure 70: Bladder Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2010
Figure 71: Bladder Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2010
Figure 72: Bladder Cancer Therapeutics Market, Italy, Sales Value ($m), 2011-2020
Figure 73: Bladder Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020
Figure 74: Bladder Cancer Therapeutics Market, Italy, Patient Volume (absolute), 2011-2020
Figure 75: Bladder Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011-2020
Figure 76: Bladder Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011–2020
Figure 77: Bladder Cancer Therapeutics Market, Italy, Drug Sales ($m), 2001-2020
Figure 78: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2001–2010
Figure 79: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001–2010
Figure 80: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2001–2010
Figure 81: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2001–2010
Figure 82: Bladder Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2010
Figure 83: Bladder Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2010
Figure 84: Bladder Cancer Therapeutics Market, Spain, Sales Value ($m), 2011-2020
Figure 85: Bladder Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020
Figure 86: Bladder Cancer Therapeutics Market, Spain, Patient Volume (absolute), 2011-2020
Figure 87: Bladder Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011-2020
Figure 88: Bladder Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011–2020
Figure 89: Bladder Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2020
Figure 90: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2001–2010
Figure 91: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2010
Figure 92: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2001–2010
Figure 93: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2001–2010
Figure 94: Bladder Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2010
Figure 95: Bladder Cancer Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2010
Figure 96: Bladder Cancer Therapeutics Market, Japan, Sales Value ($m), 2011-2020
Figure 97: Bladder Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020
Figure 98: Bladder Cancer Therapeutics Market, Japan, Patient Volume (absolute), 2011-2020
Figure 99: Bladder Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011-2020
Figure 100: Bladder Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011–2020
Figure 101: Bladder Cancer Therapeutics Market, Japan, Drug Sales ($m), 2001-2020
Figure 102: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2010
Figure 103: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2010
Figure 104: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2001–2010
Figure 105: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2010
Figure 106: Bladder Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2010
Figure 107: Bladder Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2010
Figure 108: Bladder Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011-2020
Figure 109: Bladder Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020
Figure 110: Bladder Cancer Therapeutics Market, Brazil, Patient Volume (absolute), 2011-2020
Figure 111: Bladder Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020
Figure 112: Bladder Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011–2020
Figure 113: Bladder Cancer Therapeutics Market, Brazil, Drug Sales ($m), 2001-2020
Figure 114: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2001–2010
Figure 115: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2010
Figure 116: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2001–2010
Figure 117: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2010
Figure 118: Bladder Cancer Therapeutics Market, India, Market Drivers and Restraints, 2010
Figure 119: Bladder Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2010
Figure 120: Bladder Cancer Therapeutics Market, India, Sales Value ($m), 2011-2020
Figure 121: Bladder Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020
Figure 122: Bladder Cancer Therapeutics Market, India, Patient Volume (absolute), 2011-2020
Figure 123: Bladder Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011-2020
Figure 124: Bladder Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 2011–2020
Figure 125: Bladder Cancer Therapeutics Market, India, Drug Sales ($m), 2001-2020
Figure 126: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2001–2010
Figure 127: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2010
Figure 128: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2001–2010
Figure 129: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2010
Figure 130: Bladder Cancer Therapeutics Market, China, Market Drivers and Restraints, 2010
Figure 131: Bladder Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2010
Figure 132: Bladder Cancer Therapeutics Market, China, Sales Value ($m), 2011-2020
Figure 133: Bladder Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020
Figure 134: Bladder Cancer Therapeutics Market, China, Patient Volume (absolute), 2011-2020
Figure 135: Bladder Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011-2020
Figure 136: Bladder Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 2011–2020
Figure 137: Bladder Cancer Therapeutics Market, China, Drug Sales ($m), 2001-2020
Figure 138: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2010
Figure 139: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2010
Figure 140: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2001–2010
Figure 141: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2010
Figure 142: Bladder Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2010
Figure 143: Bladder Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2010
Figure 144: Bladder Cancer Therapeutics Market, Russia, Sales Value ($m), 2011-2020
Figure 145: Bladder Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020
Figure 146: Bladder Cancer Therapeutics Market, Russia, Patient Volume (absolute), 2011-2020
Figure 147: Bladder Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020
Figure 148: Bladder Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011–2020
Figure 149: Bladder Cancer Therapeutics Market, Russia, Drug Sales ($m), 2001-2020
Figure 150: Opportunity and Unmet Need in the Superficial Bladder Cancer Therapeutics Market, 2010
Figure 151: Opportunity and Unmet Need in the Neoadjuvant Treatment of Bladder Cancer, 2010
Figure 152: Opportunity and Unmet Need in the Metastatic Bladder Cancer, 2010
Figure 153: Strategic Competitor Assessment of the Major Marketed Products in Bladder Cancer, 2010
Figure 154: Technology Trends Analytic Framework of the Bladder cancer Pipeline, 2010
Figure 155: Technology Trends Analytic Framework Description of the Bladder Cancer Pipeline, 2010
Figure 156: Bladder Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 157: Bladder Cancer Therapeutics Market – Pipeline by Clinical Phase of Development
Figure 158: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011
Figure 159: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011
Figure 160: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011
Figure 161: Bladder Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011
Figure 162: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011
Figure 163: Bladder Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011
Figure 164: Implications for Future Market Competition in the Bladder Cancer Therapeutics Market, 2010
Figure 165: Bladder Cancer, Global, BMS, SWOT Analysis 2010
Figure 166: Bladder Cancer, Global, Spectrum Pharmaceuticals, SWOT Analysis 2010
Figure 167: Bladder Cancer, Global, Bioniche Life Sciences Inc., SWOT Analysis 2010
Figure 168: Bladder Cancer, Global, Endo Pharmaceuticals, SWOT Analysis 2010
Figure 169: Bladder Cancer, Sanofi-aventis, SWOT Analysis 2010
Figure 170: Bladder Cancer, Eli Lilly and Co., SWOT Analysis 2010
Figure 171: Bladder Cancer, the US, Key Data Inputs from KOL Interviews, August 2010
Figure 172: Bladder Cancer, The UK, Key Data Inputs from KOL Interviews, August 2010
Figure 173: Bladder Cancer, Germany, Key Data Inputs from KOL Interviews, August 2010
Figure 174: Bladder Cancer, France, Key Data Inputs from KOL Interviews, August 2010
Figure 175: GlobalData Market Forecasting Model